JP2016520075A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520075A5
JP2016520075A5 JP2016513387A JP2016513387A JP2016520075A5 JP 2016520075 A5 JP2016520075 A5 JP 2016520075A5 JP 2016513387 A JP2016513387 A JP 2016513387A JP 2016513387 A JP2016513387 A JP 2016513387A JP 2016520075 A5 JP2016520075 A5 JP 2016520075A5
Authority
JP
Japan
Prior art keywords
concentration
formulation
vwf
binding agent
tween
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016513387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520075A (ja
JP6433986B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/060107 external-priority patent/WO2014184352A1/en
Publication of JP2016520075A publication Critical patent/JP2016520075A/ja
Publication of JP2016520075A5 publication Critical patent/JP2016520075A5/ja
Priority to JP2018209611A priority Critical patent/JP6952019B2/ja
Application granted granted Critical
Publication of JP6433986B2 publication Critical patent/JP6433986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016513387A 2013-05-17 2014-05-16 免疫グロブリン単一可変ドメインの安定製剤及びその使用 Active JP6433986B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018209611A JP6952019B2 (ja) 2013-05-17 2018-11-07 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361824523P 2013-05-17 2013-05-17
US61/824,523 2013-05-17
PCT/EP2014/060107 WO2014184352A1 (en) 2013-05-17 2014-05-16 Stable formulations of immunoglobulin single variable domains and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018209611A Division JP6952019B2 (ja) 2013-05-17 2018-11-07 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Publications (3)

Publication Number Publication Date
JP2016520075A JP2016520075A (ja) 2016-07-11
JP2016520075A5 true JP2016520075A5 (2) 2017-06-15
JP6433986B2 JP6433986B2 (ja) 2018-12-05

Family

ID=49304267

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016513387A Active JP6433986B2 (ja) 2013-05-17 2014-05-16 免疫グロブリン単一可変ドメインの安定製剤及びその使用
JP2018209611A Active JP6952019B2 (ja) 2013-05-17 2018-11-07 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018209611A Active JP6952019B2 (ja) 2013-05-17 2018-11-07 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Country Status (25)

Country Link
US (2) US10035862B2 (2)
EP (2) EP3511018B1 (2)
JP (2) JP6433986B2 (2)
KR (1) KR102166399B1 (2)
CN (3) CN110063935B (2)
AU (3) AU2014267222B2 (2)
BR (1) BR112015028411B1 (2)
CA (1) CA2912670A1 (2)
CY (1) CY1122090T1 (2)
DK (1) DK2996720T3 (2)
ES (2) ES2731922T3 (2)
HR (1) HRP20190954T1 (2)
HU (1) HUE044392T2 (2)
LT (1) LT2996720T (2)
MX (2) MX387527B (2)
NL (1) NL1040254C2 (2)
PH (1) PH12015502591B1 (2)
PL (2) PL3511018T3 (2)
PT (2) PT2996720T (2)
RS (1) RS58857B1 (2)
RU (1) RU2671977C2 (2)
SI (1) SI2996720T1 (2)
SM (1) SMT201900359T1 (2)
TR (1) TR201908663T4 (2)
WO (1) WO2014184352A1 (2)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
CN111035754A (zh) * 2016-03-23 2020-04-21 兆科药业（合肥）有限公司 抗血小板溶栓素在制备治疗血栓性血小板减少性紫癜的药物中的应用
GB201612043D0 (en) 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
TWI784982B (zh) * 2016-11-02 2022-12-01 開曼群島商北極星藥業集團股份有限公司 聚乙二醇化精胺酸脫亞胺酶之調配物
EP3749696A1 (en) 2018-02-06 2020-12-16 Ablynx N.V. Methods of treating initial episode of ttp with immunoglobulin single variable domains
CN112805238A (zh) 2018-07-03 2021-05-14 芬内克制药股份有限公司 无水硫代硫酸钠和其调配物
JP7653352B2 (ja) * 2018-09-05 2025-03-28 エクスプレステック、リミテッド、ライアビリティ、カンパニー 免疫グロブリンａ製剤
SG11202103670XA (en) * 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CN110564841A (zh) * 2019-09-19 2019-12-13 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 脑缺血相关基因作为缺血性卒中行为学特征分析的生物标记的应用
CN110624105B (zh) * 2019-09-24 2021-06-11 苏州大学 血管性血友病因子的结构敏感多肽抗原的序列
JP7502861B2 (ja) * 2019-12-27 2024-06-19 旭化成株式会社 標的物質と両親媒性高分子との複合体の形成反応の反応温度の評価方法
CN113908254B (zh) * 2021-10-19 2024-05-28 山西锦波生物医药股份有限公司 一种干粉吸入剂及其制备方法和用途
CN115850493B (zh) * 2022-11-08 2024-03-12 江苏耀海生物制药有限公司 一种二价纳米抗体Cablivi的分离纯化方法
WO2025240928A1 (en) * 2024-05-16 2025-11-20 Vega Therapeutics, Inc. Treatment of von willebrand disease

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
MX9605717A (es) 1994-05-18 1998-05-31 Inhale Therapeutic Syst Metodos y composiciones para la formulacion de polvo seco de interferones.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
EP1141711A1 (en) 1999-01-05 2001-10-10 Unilever Plc Binding of antibody fragments to solid supports
DK1144616T4 (da) 1999-01-19 2009-03-30 Unilever Nv Fremgangsmåde til fremstilling af antistoffragmenter
CA2361678A1 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
DE60035163T2 (de) 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
CA2370351A1 (en) 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
CN100513570C (zh) 1999-06-18 2009-07-15 Cv治疗公司 结合框运输蛋白abc1的调节作用
IL147920A0 (en) 1999-08-02 2002-08-14 Keygene Nv Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
WO2001040310A2 (en) 1999-11-29 2001-06-07 Unilever Plc Immobilisation of proteins using a polypeptide segment
ES2331051T3 (es) 1999-11-29 2009-12-21 Bac Ip B.V. Inmovilizacion de moleculas de union de antigenos de un dominio.
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
US6723359B2 (en) 2001-10-18 2004-04-20 Firmenich Sa Spray-dried compositions and method for their preparation
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP1456237A2 (en) 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006074947A2 (en) 2005-01-14 2006-07-20 Ablynx N.V. METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) * 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
CA2611726C (en) * 2005-06-10 2017-07-11 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(fv)2
US20110059101A9 (en) 2006-03-13 2011-03-10 Ablynx N.V. Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
EP2136839A4 (en) * 2007-03-22 2010-04-07 Imclone Llc STABLE ANTIBODY FORMULATIONS
SG187410A1 (en) * 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations
CA2711984A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Powdered protein compositions and methods of making same
EP2252303A2 (en) * 2008-03-21 2010-11-24 Ablynx NV Von willebrand factor specific binders and methods of use therefor
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
EP2349314B1 (en) * 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
CA2738243C (en) * 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US20120321640A1 (en) 2009-12-01 2012-12-20 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
DK2533761T3 (da) * 2010-02-11 2019-06-24 Ablynx Nv Fremgangsmåder og sammensætninger til fremstilling af aerosoler
US20120225072A1 (en) * 2011-03-02 2012-09-06 Ablynx N.V. Stable formulations of immunoglobulin single variable domains and uses thereof
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.

Similar Documents

Publication Publication Date Title
JP2016520075A5 (2)
RU2015154214A (ru) Стабильные композиции иммуноглобулинового одиночного вариабельного домена и их применение
PH12017500844A1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
JP2015231997A5 (2)
JP2013079270A5 (2)
JP2015091902A5 (2)
EA201892446A1 (ru) Фармацевтическая композиция
JP2013543505A5 (2)
JP2016534052A5 (2)
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
JP2012136518A5 (2)
WO2013164789A3 (en) Lyophilised and aqueous anti-cd40 antibody formulations
AR082171A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ngf
TN2009000382A1 (en) Stable antibody formulations
RU2017101667A (ru) Фармацевтические композиции
CN102892424A (zh) 病毒颗粒的稳定
JP2017514868A5 (2)
HRP20201242T1 (hr) Tekući farmaceutski pripravak
RU2014124143A (ru) Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения
HRP20220011T1 (hr) Nova stabilna formulacija za fxia protutijela
HRP20211838T1 (hr) Krnji protein vp4 rotavirusa i njegova primjena
EA202092926A2 (ru) Лиофилизированные составы, содержащие фактор ix
HRP20181021T1 (hr) Formulacija za bispecifične aktivatore limfocita t (bites)
RU2019111152A (ru) Новый способ стабилизации биофармацевтического лекарственного продукта при производстве
JP2016534062A5 (2)